Literature DB >> 10073729

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

P Berglund1, M N Fleeton, C Smerdou, P Liljeström.   

Abstract

The replicon of Semliki Forest virus (SFV) offers the possibility to direct high-level, transient expression of heterologous proteins in vivo. We initiated studies to determine the possibility of employing the SFV expression system for recombinant vaccine purposes. Mice immunized with recombinant SFV encoding Influenza A nucleoprotein (NP) or E. coli LacZ developed long-lasting antigen-specific IgG levels and induction of cytotoxic T-cell (CTL) memory that persisted for over one year. Predominantly type 1 T-helper cells were induced as shown by IgG subclass ELISA. Humoral and cell-mediated immune responses could be induced upon delivery by several administration routes and mucosal immunizations induced secretory IgA in the respiratory tract. Development of immune responses against the vector itself did not inhibit boost responses by subsequent immunizations with recombinant SFV. Immunization of mice with vectors encoding the Influenza A virus antigens nucleoprotein (NP) and hemagglutinin (HA) resulted in immune responses that were protective against challenge infection with Influenza virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073729     DOI: 10.1016/s0264-410x(98)00224-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Authors:  Joseph M Thompson; Alan C Whitmore; Jennifer L Konopka; Martha L Collier; Erin M B Richmond; Nancy L Davis; Herman F Staats; Robert E Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

2.  Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.

Authors:  Asa S Hidmark; Eva K L Nordström; Pia Dosenovic; Mattias N E Forsell; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Authors:  Maria Lisa Knudsen; Karl Ljungberg; Maria Kakoulidou; Linda Kostic; David Hallengärd; Juan García-Arriaza; Andres Merits; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 5.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

6.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Authors:  Francesca Avogadri; Taha Merghoub; Maureen F Maughan; Daniel Hirschhorn-Cymerman; John Morris; Erika Ritter; Robert Olmsted; Alan N Houghton; Jedd D Wolchok
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

9.  Viral alteration of cellular translational machinery increases defective ribosomal products.

Authors:  Peter Berglund; Diana Finzi; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

10.  Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

Authors:  Alonzo D García; Clement A Meseda; Anne E Mayer; Arunima Kumar; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2007-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.